Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking (Nasdaq: VKTX) reported Q1 2026 results and clinical progress on April 29, 2026. Key items: VK2735 VANQUISH-1 fully enrolled (>4,500 patients) and VANQUISH-2 fully enrolled (~1,000 patients); oral Phase 3 for VK2735 expected 4Q26. IND filed for amylin agonist VK3019 with Phase 1 planned in 2Q26. Cash, cash equivalents and short-term investments were $603 million at March 31, 2026. R&D expense was $150.2M and net loss was $158.3M for Q1 2026.
Viking Therapeutics (NASDAQ: VKTX) will release first-quarter 2026 financial results after market close on Wednesday, April 29, 2026. A conference call to discuss results and corporate updates will begin at 4:30 p.m. ET the same day.
Live webcast access is available via Viking's Webcasts page. A telephone replay is accessible until May 6, 2026, and an archived webcast will remain on the Webcasts page for 30 days.
Viking Therapeutics (NASDAQ: VKTX) will attend multiple investor conferences in April 2026, holding management 1-on-1 meetings with investors and analysts. Events and dates: Raymond James Biotech/BioPharma Conference on April 14, 2026 in New York, and Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston.
Viking Therapeutics (NASDAQ: VKTX) announced completion of enrollment in the Phase 3 VANQUISH-2 trial of subcutaneous VK2735, a GLP-1/GIP dual agonist. The randomized, double-blind, placebo-controlled study enrolled ~1,000 adults with type 2 diabetes and obesity/overweight, with 78-week dosing and a primary endpoint of percent body weight change at week 78.
The trial randomized participants to VK2735 7.5 mg, 12.5 mg, 17.5 mg or placebo, includes a 52-week extension, and follows VANQUISH-1 (enrollment completed Nov 2025). Phase 1 maintenance dosing results are expected in Q3 2026.
Viking Therapeutics (NASDAQ: VKTX) announced participation at two investor conferences in Miami the week of March 8–11, 2026. Management will hold a fireside chat on March 10, 2026 at 10:40–11:10 a.m. ET at the Leerink Partners Global Healthcare Conference and conduct 1-on-1 investor meetings at Leerink and the Jefferies Biotech on the Beach Summit (March 10–11).
A live webcast of the Leerink fireside chat will be available via the company's Investors & Media — Webcasts page, with a replay posted on the website after the conference.
Viking Therapeutics (Nasdaq: VKTX) reported Q4 and full-year 2025 results and provided a corporate update highlighting rapid clinical progress in obesity programs.
Key points: strong cash position of $706 million, VANQUISH-1 enrollment >4,500, oral VK2735 to enter Phase 3 in 3Q26, maintenance dosing study fully enrolled with data expected 3Q26, and an IND for a dual amylin/calcitonin agonist planned in 1Q26.
Viking Therapeutics (NASDAQ: VKTX) will release fourth-quarter and year-end 2025 financial results after market close on Wednesday, February 11, 2026. A conference call to discuss results and corporate updates begins at 4:30 p.m. ET the same day.
Investors can join by phone or listen via webcast at the company's Webcasts page; a telephone replay is available through February 18, 2026 and the webcast archive will remain on the site for 30 days.
Viking Therapeutics (NASDAQ: VKTX) announced publication in Obesity of Phase 2 VENTURE results for weekly subcutaneous VK2735, a dual GLP-1/GIP receptor agonist. The 13-week trial met its primary and secondary endpoints, showing mean body-weight reductions up to 14.7% from baseline with no plateau and a safety profile in which most adverse events were reported as mild or moderate. Viking is advancing VK2735 in the registrational VANQUISH Phase 3 program (78-week dosing); VANQUISH-1 has ~4,650 participants enrolled and VANQUISH-2 is enrolling ~1,100. An exploratory maintenance study (≈180 subjects) also completed enrollment.
Viking Therapeutics (NASDAQ: VKTX) announced completion of enrollment in a Phase 1 maintenance dosing study of VK2735, a dual GLP-1/GIP agonist being developed in oral and subcutaneous formulations for obesity. The randomized, double-blind, placebo-controlled study enrolled ~180 adults (BMI ≥30) who received 19 weeks of weekly VK2735 or placebo, then were randomized to maintenance regimens including monthly, every-other-week, weekly subcutaneous, daily or weekly oral dosing, or placebo through Week 31. Objectives include safety, tolerability, and pharmacokinetics; exploratory endpoints assess body-weight change from baseline and from Week 19. Viking also notes ongoing Phase 3 VANQUISH-1 (≈4,650 enrolled) and VANQUISH-2 (≈1,100 planned) studies of weekly subcutaneous VK2735 for up to 78 weeks, with results expected later in 2026.
Viking Therapeutics (NASDAQ: VKTX) announced on January 7, 2026 the appointment of Neil Aubuchon as chief commercial officer. Aubuchon brings more than two decades of global commercialization and marketing experience across Amgen, Eli Lilly and most recently as CCO at AbCellera.
The company said Aubuchon will lead commercialization strategy for VK2735, described as a potentially best-in-class GLP-1/GIP dual agonist currently in Phase 3 trials for obesity, and will support partner engagement and market preparation.